NCT01089751View on ClinicalTrials.gov

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

PHASE4CompletedINTERVENTIONAL
Enrollment

322

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Overactive Bladder
Interventions
DRUG

trospium chloride

Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks

DRUG

placebo

Placebo once daily on an empty stomach for 14 weeks.

Trial Locations (1)

Unknown

La Mesa

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01089751 - Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily | Biotech Hunter | Biotech Hunter